- The FDA approves Abbott's (NYSE:ABT) HeartMate 3 Left Ventricular Assist Device (LVAD) as a destination therapy in patients with advanced heart failure. Doctors can now prescribe the device for patients not eligible for transplant who will have the device for the remainder of their lives.
- Shares are up a fraction premarket.
FDA OKs Abbott's HeartMate 3 LVAD
Recommended For You
More Trending News
About ABT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ABT | - | - |
Abbott Laboratories |